All In Biotech

Drug Trial Radar · NCT03427814

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Jul 3, 2018

Primary completion

Jun 18, 2020

Study completion Jan 3, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.

Conditions

  • Advanced or Inoperable Gastric Cancer

Interventions

  • PamiparibDrug

    60 mg orally twice daily

  • PlaceboDrug

    60 mg orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Investigator AssessmentTime frame: Approximately 23 months

Locations

65 sites in 16 countries. Site status is shown where the registry gives one.

  • Miami Cancer Institute

    Miami, Florida

  • Scri Florida Cancer Specialist East

    West Palm Beach, Florida

  • Goshen Center For Cancer Care

    Goshen, Indiana

  • Cancer Center of Kansas

    Wichita, Kansas

  • Norton Cancer Institute

    Louisville, Kentucky

  • Novant Health Hematology Charlotte

    Charlotte, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Ballarat Oncology and Haematology Services

    Wendouree, Victoria, Australia

  • St John of God Health Care

    Subiaco, Western Australia, Australia

  • Az Sint Jan Brugge

    Bruges, Belgium

  • University Hospitals Leuven

    Leuven, Belgium

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The Affiliated Hospital of Qingdao University Branch South

    Qingdao, Shandong, China

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Fakultni Nemocnice Bulovka

    Prague, Czechia

  • Chru de Brest Hospital Morvan

    Brest, France

  • Chu Besancon Hopital Jean Minjoz

    Doubs, France

  • Hopital Prive Jean Mermoz

    Lyon, France

  • Icm Val Daurelle Oncologie Medicale

    Montpellier, France

  • Hopital Prive Des Cotes Darmor Service Oncologie

    Plérin, France

  • Centre Eugene Marquis

    Rennes, France

  • Ico Site Rene Gauducheau

    SaintHerblain, France

  • Iuc Toulouse Oncopole

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Acad Fridon Todua Medical Center Ltd Research Institute of Clinical Medicine Ltd

    Tbilisi, Georgia

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Orszagos Onkologiai Intezet

    Budapest, Hungary

  • Pecsi Tudomanyegyetem Klinikai Kozpont

    Pécs, Hungary

  • Nho Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan

  • Kindai University Nara Hospital

    Ikoma, Nara, Japan

  • Oita University Hospital

    Yufushi, Oita Prefecture, Japan

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.